Engineered CH2 domains (nanoantibodies)

mAbs

Volumn 1, Issue 1, 2009, Pages 26-28

  Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibodies; CH2; Fabs; Nanoantibodies; Scaffold

Indexed keywords

DOMAIN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; NANOANTIBODY; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIGEN BINDING; CH2 DOMAIN; HUMAN; NONHUMAN; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW;

HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; NANOPARTICLES; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY;

EID: 67649700796     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.1.7480     Document Type: Review

References (14)

1. Kolmar H and Skerra A. Alternative binding proteins get mature: rivalling antibodies. FEBS J 2008; 275:2667. (Pubitemid 351678677)
2. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007; 18:295-304. (Pubitemid 47385180)
3. Nygren PA and Skerra A. Binding proteins from alternative scaffolds. J Immunol Methods 2004; 290:3-28.
4. Binz HK, Amstutz P and Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005; 23:1257-1268 (Pubitemid 41486853)
5. Hey T, Fiedler E, Rudolph R and Fiedler M. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol 2005; 23:514-522 (Pubitemid 41317915)
6. Holliger P and Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-1136 (Pubitemid 41486394)
7. Holt LJ, Herring C, Jespers LS, Woolven BP and Tomlinson IM. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21:484-490
8. Saerens D, Ghassabeh GH and Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 2008; 8:600-608
9. Chen W, Zhu Z, Feng Y, Xiao X and Dimitrov DS. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 2008; 382:779-789
10. Chen W, Zhu Z, Feng Y and Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008; 105:17121-17126
11. Feige MJ, Walter S and Buchner J. Folding mechanism of the CH2 antibody domain. J Mol Biol 2004; 344:107-118 (Pubitemid 39422377)
12. Prabakaran P, Vu BK, Gan J, Feng Y, Dimitrov DS and Ji X. Crystal structure of an isolated, unglycosylated antibody CH2 domain. Acta Crystallogr B 2008; 64:1062-1067
13. Vu BK, Walsh J, Dimitrov DS and Ishima R. Dynamics of antibody domains studied by solution NMR. Meth Mol Biol 2008; In press.
14. Martin WL, West AP Jr, Gan L and Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7:867-877 (Pubitemid 32436446)